Figure 5 | Scientific Reports

Figure 5

From: E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments

Figure 5

Effects of ly101-4B and HLM006474 on E2F high and low activity PDAC derived cell lines. (a,b) Three E2F high activity cell lines (in red) and four E2F low activity cell lines (in blue) were tested for their viability upon a 72 h treatment with both drugs. Cell viability was measured using the PrestoBlue reagent according to the manufacturer. Data are expressed as percentage relative to vehicle treated conditions in at least two independents experiments made in triplicates. (b,d) IC50 values were calculated by non-linear regression curves with robust fit using GraphPad software. Data are mean ± SEM.

Back to article page